SCHEMBL7059925

SCHEMBL7059925

NS(=O)(=O)c1ccccc1-n1ncc(Cl)c1-c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 9/20 0.64
PTGS1 P23219 8/20 0.64
CA2 P00918 8/20 0.46
CA12 O43570 7/20 0.46
CA9 Q16790 7/20 0.46
CA1 P00915 6/20 0.46
CA7 P43166 3/20 0.43
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MAOB P27338 1/20 0.39
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA13 Q8N1Q1 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
NPC1 O15118 1/20 0.37
MITF O75030 1/20 0.37
S1PR4 O95977 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8639255 0.92 PTGS2 (0.54) PTGS2PTGS1CA2CA12CA9
SCHEMBL8693265 0.90 PTGS2 (0.52) PTGS2PTGS1CA2CA12CA9
SCHEMBL8689254 0.90 PTGS2 (0.52) PTGS2PTGS1CA2CA12CA9
SCHEMBL8692201 0.86 HTT (0.49) PTGS2PTGS1CA2CA12CA9
SCHEMBL8693825 0.84 PTGS2 (0.46) PTGS2PTGS1CA2CA12CA9
SCHEMBL8688579 0.83 PTGS2 (0.64) PTGS2PTGS1CA2CA12CA9
SCHEMBL8691852 0.83 PTGS2 (0.64) PTGS2PTGS1CA2CA12CA9
SCHEMBL8691904 0.81 PTGS2 (0.49) PTGS2PTGS1CA2CA12CA9
SCHEMBL7773923 0.81 PTGS2 (0.52) PTGS2PTGS1CA2CA9CA1
SCHEMBL8688908 0.80 PTGS2 (0.43) PTGS2PTGS1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2001527542-A 2001-12-25 JP claimed
EP-0979077-A1 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS G.D. Searle & Co. (US) 2000-02-16 EP claimed
WO-1998047509-A1 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1998-10-29 WO claimed
US-5760068-A NONSTEROIDAL ANTIINFLAMMATORY AGENTS WITH REDUCED SIDE EFFECTS G.D. SEARLE & CO. (US) 1998-06-02 US claimed
EP-1443967-A1 CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION Novartis AG (CH) 2004-08-11 EP disclosed
WO-2003039599-A1 CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION NOVARTIS AG (CH) 2003-05-15 WO disclosed
US-5760068-A NONSTEROIDAL ANTIINFLAMMATORY AGENTS WITH REDUCED SIDE EFFECTS G.D. SEARLE & CO. (US) 1998-06-02 US disclosed
US-5756529-A ANTIINFLAMMATORY G.D. SEARLE & CO. (US) 1998-05-26 US disclosed